42 results
6-K
EX-99.1
MDNAF
Medicenna Therapeutics Corp.
9 Apr 24
Current report (foreign)
2:05pm
(TME) to maximize efficacy and minimize systemic toxicity
MDNA113 is our most advanced pre-clinical candidate that targets IL-13Rα2, a tumor
6-K
EX-99.1
MDNAF
Medicenna Therapeutics Corp.
10 Oct 23
Medicenna Therapeutics Appoints Humphrey Gardner, M.D., as Chief Medical Officer
8:57am
has started the Phase 2 dose expansion trial with MDNA11, our potential best-in-class, next-generation IL-2 super-agonist that targets solid tumors
6-K
EX-99.1
MDNAF
Medicenna Therapeutics Corp.
28 Aug 23
Current report (foreign)
4:49pm
or otherwise.
A-7
The Board has not adopted targets regarding the representation of women and other members of Designated Groups on the Board … of the individual and the needs of the Corporation at the relevant time. In addition, targets based on specific criteria such as gender could limit the Board’s
6-K
EX-99.2
MDNAF
Medicenna Therapeutics Corp.
28 Jul 23
Interim condensed consolidated financial statements of
8:31am
molecule allows us to simultaneously engage both of these important targets on the same immune cells (also known as cis-binding).
On September 22, 2022
6-K
EX-99.2
bt8h ez90kffem
4 Nov 22
Interim condensed consolidated financial statements of
8:00am
6-K
EX-99.1
ngsg7v
22 Aug 22
Current report (foreign)
11:39am
6-K
EX-99.2
2jttjtlbgtz
15 Aug 22
Interim Condensed Consolidated Statements of Financial Position
8:00am
SUPPL
tctbu
10 Aug 22
Supplemental materials (foreign)
3:10pm
SUPPL
c2muty
8 Aug 22
Supplemental materials (foreign)
8:40pm
20-F
EX-4.7
2eoj0ceq
22 Jun 22
Annual report (foreign)
5:04pm
20-F
67rmk 11pjf144
22 Jun 22
Annual report (foreign)
5:04pm
20-F
EX-15.1
00wc0nkv9 7645o1qd
22 Jun 22
Annual report (foreign)
5:04pm
6-K
EX-99.1
m6fld8vg jfts
22 Jun 22
Current report (foreign)
8:00am
6-K
EX-99.3
5hh5eed2cw
22 Jun 22
Current report (foreign)
8:00am
6-K
EX-99.1
9cc h1srr
9 Mar 22
Medicenna Announces Upcoming Poster Presentations at the AACR Annual Meeting
7:15am
6-K
EX-99.5
7o6u9qysn741q6rq
9 Feb 22
Interim condensed consolidated financial statements of
7:18am
6-K
EX-99.2
j1qvls 2ls8gjj20
9 Feb 22
Interim condensed consolidated financial statements of
7:18am
6-K
EX-99.2
s70 exkea0cbn1bxu
12 Nov 21
Interim condensed consolidated financial statements of
7:15am